Toggle navigation EN

Publikationen 2013

  1. Graff J and Harder S. Anticoagulant Therapy with the Oral Direct Factor Xa  Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran in Patients with Hepatic Impairment. Clinical Pharmacokinetics 2013 Feb 7. [Epub ahead of print]
  2. Höffken O, Haussleiter IS, Westermann A, Lötsch J, Maier C, Tegenthoff M, and Schwenkreis P. Influence of (S)-ketamine on human motor cortex excitability. Experimental Brain Research 2013 (accepted)
  3. Pickert G, Lim HY, Weigert A, Häussler A, Myrczek T, Waldner M, Labocha S, Ferreirós N, Geisslinger G, Lötsch J, Becker C, Brüne B, and Tegeder I. Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer 2013 Feb 1;132(3):591-604
  4. Doehring A, Oertel BG, Sittl R, and Lötsch J. Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain 2013 Jan;154(1):15-23
  5. Becker A, Geisslinger G, Murín R, Grecksch G, Höllt V, Zimmer A, Schröder H. Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 2013 (in press)
  6. Kynast KL, Russe OQ, Möser CV, Geisslinger G, and Niederberger E. Modulation of central nervous system-specific microRNA-124a alters the inflammatory response in the formalin test in mice. Pain 2013 (in press)
  7. Brenneis C, Kistner K, Puopolo M, Segal D, Roberson D, Sisignano M, Labocha S, Ferreirós N, Strominger A, Cobos EJ, Ghasemlou N, Geisslinger G, Reeh PW, Bean BP, Woolf CJ. Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J Neurosci 2013 Jan 2;33(1):315-26
  8. Niederberger E, Möser C, Kynast K, and Geisslinger G. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs. Curr Mol Med 2013 (in press)
  9. Kallenborn-Gerhardt W, Schröder K, Geisslinger G, and Schmidtko A. NOXious signaling in pain processing. Pharmacol Ther 2013 (in press)
  10. Ferreirós N, Labocha S, Walter C, Lötsch J, and Geisslinger G. Simultaneous and sensitive LC-MS/MS determination of tetrahydrocannabinol and its metabolites in human plasma. Analyt Bioanalyt Chem 2013 Feb;405(4):1399-406
  11. Lötsch J, Walter C, Parnham MJ, Oertel BG, and Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet 2013 Jan;52(1):23-36
  12. Walter C, Ferreiros N, Bishay P, Geisslinger G, Tegeder I, and Lötsch J. Exogenous Delta-9-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans. J Clin Psychopharmacol. 2013 Jul 29. [Epub ahead of print]
  13. Kallenborn-Gerhardt W, Lu R, Syhr KM, Heidler J, von Melchner H, Geisslinger G, Bangsow T, and Schmidtko A. Antioxidant activity of Sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal (im Druck)
  14. Lötsch J, Doehring A, Mogil JS, Arndt T, Geisslinger G, and Ultsch A. Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther 2013 Jul;139(1):60-70
  15. Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013 Apr 26. [Epub ahead of print]
  16. Kynast KL, Russe OQ, Geisslinger G, and Niederberger E. Novel findings in pain processing pathways: implications for microRNAs as future therapeutic targets. Expert Review of Neurotherapeutics 2013 (accepted)
  17. Niederberger E, and Geisslinger G. Proteomics and NF-kB: an update. Expert Review of Proteomics 2013 (accepted)
  18. Kynast KL, Russe OQ, Möser CV, Geisslinger G, Niederberger E. Modulation of central nervous system-specific microRNA-124a alters the inflammatory response in the formalin test in mice. Pain 2013 Mar;154(3):368-76
  19. Niederberger E, Möser C, Kynast K, Geisslinger G. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs. Curr Mol Med 2012 Nov 15. [Epub ahead of print]
  20. Freynhagen R, Geisslinger G, Schug S. Opioids for chronic non-cancer pain. British Medical Journal 2013 (im Druck)
  21. Hartmann D, Wegner MS, Wanger RA, Ferreirós N, Schreiber Y, Lucks J, Schiffmann S, Geisslinger G, Grösch S. The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS. Int J Biochem Cell Biol 2013 Mar 26. [Epub ahead of print]
  22. Kahnt AS, Rörsch F, Diehl O, Hofmann B, Lehmann C, Steinbrink SD, Angioni C, Geisslinger G, Grösch S, Steinhilber D, Maier TJ. Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity. Biochem Pharmacol 2013 May 14. Epub ahead of print
  23. Buscató El, Wisniewska JM, Rödl CB, Brüggerhoff A, Kaiser A, Rörsch F, Kostewicz E, Wurglics M, Schubert-Zsilavecz M, Grösch S, Steinhilber D, Hofmann B, Proschak E. Structure-activity relationship and in vitro pharmacological evaluation of imidazo[1,2-a]pyridine-based inhibitors of 5-LO. Future Med Chem 2013 May;5(8):865-80
  24. Lötsch J, Skarke C, Darimont J, Zimmermann M, Bräutigam L, Geisslinger G, Ultsch A, and Oertel BG. Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia. Naunyn Schmiedebergs Arch Pharmacol 2013 (accepted)
  25. Heimann D, Lötsch J, Hummel T, Doehring A, and Oertel BG. Linkage between increased nociception and olfaction via a SCN9A haplotype. PLoS One 2013 Jul 10;8(7):e68654
  26. Haselbach S, Maurer J, Vogel V, Harder S, Weber CF, Baykut D, Meininger D, Keller H, Moritz A, Mäntele W. A novel method for the direct determination of heparin concentration during cardiopulmonary bypass surgery. Clin Chem Lab Med. 2013 Jun 25:1-7
  27. Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G and Niederberger N. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain 2013 (akzeptiert)
  28. Lötsch J and Ultsch A. A machine-learned knowledge discovery method for associating complex phenotypes with complex genotypes. Application to pain. J Biomed Informatics 2013 Aug 9 [Epub ahead of print]
  29. Lötsch J, Schaeffeler E, Mittelbronn M, Winter S, Gudziol V, Schwarzacher SW, Hummel T, Doehring A, Schwab M, and Ultsch A. Functional genomics suggest neurogenesis in the adult human olfactory bulb. Brain Struct Funct 2013 Aug 9. [Epub ahead of print]
  30. Muth C, Beyer M, Fortin M, Rochon J, Oswald F, Valderas JM, Harder S, Glynn LG, Perera R, Freitag M, Kaspar R, Gensichen J, van den Akker M. The case of Mr. Curran: A multi-disciplinary scoping exercise of multimorbidity’s research challenges and priorities from a clinical perspective. Eur J Gen Pract 2013 (in press)
  31. Schiffmann S, Birod K, Männich J, Eberle M, Wegner MS, Wanger R, Hartmann D, Ferreiros N, Geisslinger G and Grösch S. Ceramide metabolism in mouse tissue. Int J Biochem Cell Biol. 2013 Aug;45(8):1886-94.
  32. Lötsch J, Schneider G, Reker D, Parnham MJ, Schneider P, Geisslinger G, and Doehring A. Common non-epigenetic drugs as epigenetic modulators. Trends Mol Med 2013 Dec;19(12):742-53
  33. Schuh CD, Brenneis C, Zhang DD, Angioni C, Schreiber Y, Ferreiros-Bouzas N, Pierre S, Henke M, Linke B, Nüsing R, Scholich K, and Geisslinger G. Prostacyclin regulates spinal nociceptive processing through cyclic adenosine monophosphate-induced translocation of glutamate receptors. Anesthesiology 2013 (accepted)
  34. Walter C, Doehring A, Oertel BG, and Lötsch J. The µ-opioid receptor gene variant OPRM1 118 A>G: A summary of its molecular and clinical consequences for pain. Pharmacogenomics 2013 (accepted)
  35. Meyer dos Santos S, Zorn A, Guttenberg Z, Picard-Willems B, Kläffling C, Nelson K, Klinkhardt U, Harder S. A novel µ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants. Biomicrofluidics 2013 (accepted) 
  36. Brenneis C, Kistner K, Puopolo M,  Jo S,  David R, Sisignano M, Segal D, Cobos E, Wainger B, Labocha S, Ferreirós N, von Hehn C, Tran J, Geisslinger G, Reeh P, Bean B, and Woolf C. Bupivacaine-induced cellular entry of QX-314 and its contribution to differential nerve block. Br J Pharmacol 2013 (accepted).
  37. Juengel E, Santos SM, Schneider T, Makarevic J, Hudak L, Bartsch G, Haferkamp A, Wiesner C, Blaheta RA. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. Exp Biol Med (Maywood) 2013 Sep 4. [Epub ahead of print] 
  38. Kanngiesser M, Mair N, Lim H, Zschiebsch K, Blees JS, Häussler A, Brüne B, Ferreiròs N, Kress M, Tegeder I. Hypoxia inducible factor 1 regulates heat and cold pain sensitivity and persistence. Antioxid Redox Signal 2013 (accepted)
  39. Albuquerque B, Häussler A, Vannoni E, Wolfer DA, and Tegeder I. Learning and memory in mice with neuropathic pain: impact of old age and progranulin deficiency. Front Behav Neurosci 2013 (accepted)
  40. Sisignano M, Angioni C, Ferreiros N, Schuh CD, Suo J, Schreiber Y, Dawes JM, Antunes-Martins A, Bennett DLH, McMahon SB, Geisslinger G, and Scholich K. Synthesis of lipid mediators during UVB-induced inflammatory hyperalgesia in rats and mice. PLOS One 2013 (accepted)
  41. Lill K, Scholich K, and Stark H. Synthesis of Novel Dansyl-Labeled Celecoxib Derivatives. Tetrahedron Lett 2013, 54(49), 6682-6686.
  42. Sisignano M, Bennett DL, Geisslinger G, and Scholich K. TRP-channels as key integrators of lipid pathways in nociceptive neurons. Progress in Lipid Research 2013 (accepted)
  43. Pierre S and Scholich K. PITOLISANT HYDROCHLORIDE histamine H-3 receptor inverse agonist treatment of sleep disorders treatment of schizophrenia. Drugs of the Future  2013  38(2):91-97 
  44. Lötsch J, Hummel T, Warskulat U, Coste O, Häussinger D, Geisslinger G, and Tegeder I. Congenital taurine deficiency in mice is associated with reduced sensitivity to nociceptive chemical stimulation. Neuroscience 2013 Dec 7;259C:63-70